IL1RN and prostate cancer: Following the idea of anti-cancer function of IL1RN [10,11], we further compared the mRNA levels of IL1RN before ADT (pre-ADT) and after ADT (post-ADT, 22 weeks after ADT) in seven prostate cancer patients [28].